Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategic partnership
Biotech
Boehringer axes MASH deal after OSE asset fails to show efficacy
The French biotech is downsizing its pipeline after its Boehringer-partnered SIRPα antagonist failed to show efficacy in a phase 2 MASH study.
Gabrielle Masson
Mar 2, 2026 2:16pm
Imunon puts COVID vaccine on ice, seeks partner amid cash crunch
Aug 5, 2025 9:55am
Antibody strengthens bones in mice with brittle bone disease
Jul 30, 2025 2:54pm
Erasca looks to partner off late-stage melanoma asset
May 13, 2025 10:38am
Catamaran Bio sends out life raft in tough financing climate
Jan 30, 2024 2:42pm
Velocity teams with Privia Health for clinical research sites
Jul 12, 2023 11:50am